@article{133fc8b41a47488eb87b52825a315d93,
title = "Multiple treatment cycles of neural stem cell delivered oncolytic adenovirus for the treatment of glioblastoma",
abstract = "Tumor tropic neural stem cells (NSCs) can improve the anti-tumor efficacy of oncovirotherapy agents by protecting them from rapid clearance by the immune system and delivering them to multiple distant tumor sites. We recently completed a first-in-human trial assessing the safety of a single intracerebral dose of NSC-delivered CRAd-Survivin-pk7 (NSC.CRAd-S-pk7) combined with radiation and chemotherapy in newly diagnosed high-grade glioma patients. The maximum feasible dose was determined to be 150 million NSC.CRAd-Sp-k7 (1.875 × 1011 viral particles). Higher doses were not assessed due to volume limitations for intracerebral administration and the inability to further concentrate the study agent. It is possible that therapeutic efficacy could be maximized by administering even higher doses. Here, we report IND-enabling studies in which an improvement in treatment efficacy is achieved in immunocompetent mice by administering multiple treatment cycles intracerebrally. The results imply that pre-existing immunity does not preclude therapeutic benefits attainable by administering multiple rounds of an oncolytic adenovirus directly into the brain.",
keywords = "Glioma, Immunotherapy, Neural stem cell, Oncolytic virus, Stem cell carrier, Viral delivery",
author = "Jennifer Batalla-Covello and Ngai, {Hoi Wa} and Linda Flores and Marisa McDonald and Caitlyn Hyde and Joanna Gonzaga and Mohamed Hammad and Margarita Gutova and Jana Portnow and Tim Synold and Curiel, {David T.} and Lesniak, {Maciej S.} and Aboody, {Karen S.} and Rachael Mooney",
note = "Funding Information: Funding: This research was funded by the City of Hope, the Anthony F. & Susan M. Markel Foundation, the Ben and Catherine Ivy Foundation, the Bob Marx Board of Governors Foundation, the Rally Foundation, the Rosaline and Arthur Gilbert Foundation, the California Institute of Regenerative Medicine (TRAN1-11544), the Alvarez Family Charitable Foundation, the H.W.N. & Frances Berger Foundation Fellowship, the Norman & Melinda Payson Fellowship, Cancer Center Support Grant (P30 CA33572), and City of Hope{\textquoteright}s Irell & Manella Graduate School of Biological Sciences. Research reported in this publication included work performed by Holly Yin from the City of Hope Molecular Pathology Core, which is supported by the National Cancer Institute of the NIH under award number P30CA033572. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).",
year = "2021",
month = dec,
day = "1",
doi = "10.3390/cancers13246320",
language = "English",
volume = "13",
journal = "Cancers",
issn = "2072-6694",
number = "24",
}